Telomir-Zn
Asset
Chelates intracellular iron, reducing iron-dependent KDM activity to promote epigenetic reprogramming and reactivate silenced tumor-suppressor genes.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Telomerase and telomere maintenance
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2TNBC
Phase 1, globenewswire.com, 6 Oct 2026
Triple-negative breast cancer
Preclinical, telomirpharma.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors4
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.